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ABSTRACT
Objective: A simple, accurate, precise, and reversed-phase high-performance liquid chromatography (RP-HPLC) method was developed and validated 
for gabapentin (GBP) and its related substances in the capsule dosage form and excipient compatibility studies.
Methods: The review of literature indicates that various methods have been reported for the estimation of GBP. When some excipients were used for 
GBP, it produced degradation product called lactam due to the presence of more water content. Hence, a novel RP-HPLC method has been developed 
for studying excipient compatibility and related substances of GBP in capsule dosage form using excipients such as lactose anhydrous and dried 
maize starch which is having less water activity. Waters Alliance e2695 separation module with ultraviolet/photodiode array (UV/PDA) detector 
with Inertsil C8 (250 mm×4.6 mm); 5 µm with an injection volume of 50 µl is injected and eluted with the (gradient program) mobile Phase A 
buffer: acetonitrile (940:60) and mobile phase B buffer: acetonitrile (700:300) pH 6.9 with 5 N potassium hydroxide which is pumped at a speed of 
1.5 ml/min and detected by UV/PDA detector at 210 nm. The peaks of GBP and GBP-related compound A are well separated at 6.7 min and 34.5 min, 
respectively.
Results: The method developed was approved for various parameters such as accuracy, specificity, precision, intermediate precision, range, linearity, 
robustness, limit of detection, limit of quantification, steadiness, and system suitability according to the International Conference on Harmonization 
guidelines. The results got were according to the acceptance criteria.
Conclusion: The technique proposed was assured for detection of related substances in the marketed formulation and could be used for the routine 
analysis of GBP and GBP-related compound A in the capsule dosage form.
Keywords: Gabapentin, Gabapentin-related compound A, Reversed-phase high-performance liquid chromatography, Validation and capsule dosage 
forms.
INTRODUCTION
Gabapentin (GBP) is chemically 2-[1-(aminomethyl)cyclohexyl]acetic 
acid as shown in Fig. 1. By expansion of a cyclohexyl group to gamma-
aminobutyric acid (GABA) GBP was formed, which allowed this form of 
GABA to cross the blood–brain barrier.
GBP was first incorporated to mimic the chemical structure of the 
neurotransmitter GABA, but it was not able to act on the similar 
cerebrum receptors.
GBP stops the formation of new synapses. GBP has been found to 
decrease calcium flow after constant application by binding to the 
α2δ subunit (1 and 2) but not by acute application through an impact 
on trafficking of voltage-dependent calcium flow in central nervous 
system. The calcium channel trafficking is another possible mechanism, 
yet the exact mechanism of action of GBP stays in dispute.
GBP obviously has a novel mechanism of action, most likely including 
potentiation of GABA - mediated inhibition and conceivably inactivation 
of sodium channels also.
The literature survey [1-21] indicates that when lactose was used as an 
excipient for GBP, it produced an impurity called lactam, due to which 
stability was affected. Hence, according to the International Conference 
on Harmonization (ICH) guidelines, an attempt was made to create and 
validate a basic simple, accurate, precise, and efficient reversed-phase 
high-performance liquid chromatography (RP-HPLC) technique for the 
excipient compatibility studies and related substances of GBP using 
lactose monohydrate and maize starch as the excipients.
METHODS
Instrumentation
High-performance liquid chromatography (waters) with quaternary 
pump, with Inertsil C8 (250 mm×4.6 mm); 5 µm column detection of 
drug carried by ultraviolet (UV) detector data processing was carried 
out by Empower - 2 Software, weighing balance (Sartorius), sonicator 
(spectra lab), and pH meter (polmon).
Reagents and chemicals
GBP working standard, GBP-related compound A, acetonitrile (HPLC 
grade), HPLC water, potassium dihydrogen orthophosphate, potassium 
hydroxide; reference standards: GBP - USP certified reference standard Fig. 1: Structure of gabapentin
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Bengaluru, GBP-related compound A - USP comprehensive ranking 
system, and excipients: Lactose monohydrate, lactose anhydrous, maize 
starch, and dried maize starch, talc were used.
Chromatographic conditions
Column: Inertsil C8 (250 mm×4.6 mm); 5 µm or equivalent
Flow rate: 1.5 ml/min
Injection volume: 50 µl
Column (oven temp): Ambient
Wavelength: UV/PDA at 210 nm
Elutiontype: Gradient.
Gradient program





The peaks of GBP and GBP-related compound A are well separated at 
6.7 min and 34.5 min, respectively.
Solution preparation
Preparation of 5N potassium hydroxide
Weigh about 28.06 g of potassium hydroxide transfer into 100 ml glass 
beaker, pour about 50 ml of purified water and dissolve it and makeup 
to 100 ml with water.
Diluent
Dissolve 1.2 g of dihydrogen potassium orthophosphate KH2PO4 
in 1000 ml of water and maintain the pH at 6.9 using 5 N potassium 
hydroxide.
Preparation of mobile phase A
Dissolve 1.2 g potassium dihydrogen orthophosphate in 940 ml of 
water. Adjust the pH to 6.9 with 5 N potassium hydroxide and add 
60 ml of acetonitrile and mix well. The solution was filtered through a 
membrane filter (0.45 µm) and degassed.
Preparation of mobile phase B
Dissolve 1.2 g potassium dihydrogen orthophosphate in 700 ml of 
water. Adjust the pH to 6.9 using 5 N potassium hydroxide and add 
300 ml of acetonitrile and mixed well. The solution was filtered through 
a membrane filter (0.45 µm) and degassed.
GBP-related compound A stock solution
Accurately weigh about 10 mg of GBP-related compound A RS in a 
volumetric flask of 20 ml volume add diluent to solubilize the content 
and makeup to the volume by using diluent.
Standard preparation
Accurately weigh 0.025 g of GBP working standard into a volumetric 
flask of 50 ml, add diluent to solubilize the content by shaking for 1 min 
and make to volume with diluent. Pipette out 2 ml of this solution and 
2 ml of GBP-related compound A stock solution into 25 ml and makeup 
to the volume with diluent and mixed well. The solution was filtered 
through a membrane filter (0.45 µm).
Calibration curves
The range and linearity of the analytical method for GBP was confirmed 
by injecting the various concentrations of GBP standard preparation 
prepared according to the range of limit of quantification (LOQ) 
covering six different concentrations up to 150% of specification level 
into the chromatograph, and the response was observed to be linear 
within that range. The linearity of GBP and each related substance was 
plotted by a graph between response factor and concentration. The 
relationship between the concentration and response was linear in the 
specified range, and the correlation coefficient was 0.99 for GBP and 
each related substance.
Sample preparation
Remove and weigh the contents of not fewer than 20 capsules. 
Transfer an accurate weighed portion of the powder, approximately to 
about 500 mg of GBP, to 25 ml volumetric flask and add about 15 ml of 
diluent. Shake for 1 min and makeup to the level using the diluent and 
then mix well. The solution was filtered through a membrane filter 
(0.45 µm). Collect the filtrate, after removing the certain amount of 
the filtrate.
Procedure
Equilibrate the column for not <30 min with an initial gradient and rate 
of flow was kept at 1.5 mL/min. Inject separately 50 µL of the above all 
solutions into the HPLC and measure the peak responses for the major 




The objective of the method validation as stated in ICH guidelines is to 
exhibit that the technique is reasonable for its intended purpose.
Accuracy (recovery studies)
By adding known quantity of known impurity, the recovery studies 
were performed standards to test solution in the range of LOQ to 150% 
of specification limit specified in the method of analysis, with four 
different concentrations (LOQ, 50%, 100%, and 150% in triplicate) 
to represent the entire range. The percentage recovery and relative 
standard deviation (RSD) for all the values of percentage recovery were 
reported. The mean percentage recovery of all known related substance 
Fig. 2: Typical graph of gabapentin
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GBP-related compound A of nine determinations over three different 
concentrations and three determinations at LOQ levels were within the 
acceptance limit is shown in Table 1.
Precision
Repeatability of analytical technique was established by assessing the 
related substances for six different test solutions of the same batch. 
The percentage of related substances for all six test solutions was 
calculated, and the percentage (RSD) for the same was reported. The 
evaluation of related substances, i.e., GBP-related Compound A, for all 
six determinations has been presented in Tables 2 and 3. Unknown 
impurity is not detected in the all six sample preparations of the sample 
batch.
Ruggedness
The ruggedness of the analytical method was confirmed by estimating 
the related substances for six different test solutions of the same batch by 
another analyst on a different HPLC system using another column on some 
another day. The percentage of related substances for all six test solutions 
was calculated, and the percentage RSD was reported for the same. The 
analytical method intermediate precision was established by estimating the 
related substances for six different samples of the same batch by another 
analyst on a different HPLC system using a column of another lot number 
on some another day. The evaluation of related substances, i.e., GBP-related 
Compound A, for all six determinations has been presented in Tables 4 
and 5. Two unique analysts carried out the analysis of the same batch 
of GBP 400 mg capsules on two distinct instruments, with two different 
columns on distinct days. The details presented in Table 6.
Linearity
The linearity of the analytical method was demonstrated by injecting 
the various concentrations of all known impurities, and GBP prepared 
according to the range of LOQ covering at least six different concentration 
levels up to 150% of specification level into the chromatograph. Regression 
analysis results of the linearity data have been presented in Table 7 and 
Figure-3. The linearity and range of the analytical method for GBP-related 
Compound A was established by injecting the various concentrations of 
GBP-related Compound A standard preparation prepared according 
to a range of LOQ, covering six different concentrations up to 150% of 
specification level into the chromatograph. Regression analysis results 
of the linearity and range of the analytical method for GBP-related 
Compound A have been presented in Table 8 and linearity graph of GBP-
related Compound A, presented in Figure-4.
Table 1: Recovery of GBP-related compound A
% Level/sample ID % of impurity added 
with respect sample 
concentration
% total impurity 
found in spiked 
sample
% mean impurity 
in control sample
% of impurity 
found with respect 
to spiked quantity
% of impurity 




LOQ level sample-1 0.0025 0.0176 0.0148 0.0028 112.00 112.0
LOQ level sample-2 0.0025 0.0176 0.0148 0.0028 112.00
LOQ level sample-3 0.0025 0.0176 0.0148 0.0028 112.00
50% level sample-1 0.1006 0.1154 0.0148 0.1006 100.00 100.0
50% level sample-2 0.1005 0. 1155 0.0148 0.1007 100.20
50% level sample-3 0.1005 0.1151 0.0148 0.1003 99.80
100% level sample-1 0.2011 0.2213 0.0148 0.2065 102.69 102.7
100% level sample-2 0.2011 0.2213 0.0148 0.2065 102.69
100% level sample-3 0.2011 0.2216 0.0148 0.2068 102.83
150% level sample-1 0.3017 0.3264 0.0148 0.3116 103.28 103.6
150% level sample-2 0.3017 0.3277 0.0148 0.3129 103.71
150% level sample-3 0.3016 0.3275 0.0148 0.3127 103.68
Overall statistical analysis For LOQ level Mean 112.0
SD 0.00
% RSD 0.0
For other levels Mean 102.1
SD 1.62
% RSD 1.6
GBP: Gabapentin, SD: Standard deviation, LOQ: Limit of quantification, RSD: Relative standard deviation
Table 2: Percentage of GBP-related compound A at RT~34.4 for six samples of the same batch
Sample ID Weight of sample 
taken (mg)
GBP-related compound A at 
RT~34.4
% of GBP-related compound A at RT~34.4 with respect to GBP-related 
compound A (standard solution)
Sample-1 662.52 41,642 0.01
Sample-2 661.30 44,841 0.01
Sample-3 661.83 45,046 0.01
Sample-4 662.92 44,172 0.01
Sample-5 661.62 43,863 0.01




GBP: Gabapentin, SD: Standard deviation, RSD: Relative standard deviation
Table 3: Percentage of total impurities for six samples of the 
same batch










SD: Standard deviation, RSD: Relative standard deviation
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Limit of detection (LOD) and LOQ
LOD and LOQ values of related substance and GBP can be predicted 
based on S/N ratio method. For this, the 100% linearity solutions of 
each related substance and GBP were considered from the respective 
linearity experiment. The signal-to-noise ratio should be 10 and 3.3 for 
LOQ and LOD, respectively. Each anticipated concentration was checked 
by setting the solutions at about anticipated concentrations and 
infusion every solution 6 times into the chromatograph independently. 
Percentage RSD for the areas obtained for the six replicate injections of 
GBP and each related substance has been given in Tables 9-12.
Specificity/selectivity
This method proves the specificity of the analytical technique for the 
estimation of related substances in GBP 400 mg capsules by HPLC. 
Table 4: Percentage of GBP-related compound A at RT~34.4 for six samples of the same batch
Sample ID Weight of sample 
taken (mg)
GBP-related compound A at 
RT~34.4
% of GBP-related compound A at RT~34.4 with respect to 
GBP-related compound A (standard solution)
Sample-1 661.53 40,925 0.01
Sample-2 660.85 36,944 0.01
Sample-3 661.36 39,602 0.01
Sample-4 661.40 39,902 0.01
Sample-5 661.62 39,154 0.01




GBP: Gabapentin, SD: Standard deviation, RSD: Relative standard deviation
Table 5: Percentage of total impurities for six samples of the 
same batch










SD: Standard deviation, RSD: Relative standard deviation
Fig. 3: Linearity graph of gabapentin
Fig. 4: Linearity graph of gabapentin related compound A
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Table 6: Intermediate precision details
Experiment name Method precision Ruggedness
Analyst Analyst 1 Analyst 2
Equipment ID FD-20 FD-21
Column ID LC004 LC005
Day November 27, 2010 December 04, 2010
Impurity name Overall impurity summary
Mean SD % RSD
GBP-related compound A 0.01 0.00 0.0
Any unknown impurity Not applicable Not applicable Not applicable
Total impurities 0.01 0.00 0.0
GBP: Gabapentin, SD: Standard deviation, RSD: Relative standard deviation
Table 7: Linearity of GBP
Percent solution with 












GBP: Gabapentin, LOQ: Limit of quantification
Table 8: Linearity of GBP-related compound A
Percent solution with 












GBP: Gabapentin, LOQ: Limit of quantification
Table 9: Range
Impurity name Range (% of specification)
GBP-relate compound A OQ to 150
GBP: Gabapentin, LOQ: Limit of quantification
Table 10: LOD and LOQ for GBP










% RSD 4.0 2.4
Con. (µg/mL) 2.244 6.801
LOD: Limit of detection, LOQ: Limit of quantification, GBP: Gabapentin, 
SD: Standard deviation, RSD: Relative standard deviation
Table 11: LOD and LOQ for GBP-related compound A










% RSD 8.3 2.7
Con. (µg/mL) 0.166 0.503
LOD: Limit of detection, LOQ: Limit of quantification, GBP: Gabapentin, 
SD: Standard deviation, RSD: Relative standard deviation
Table 13: Data from spiked sample
Name RT Peak purity
Purity angle Purity threshold
GBP 6.685 0.645 0.663
GBP-related compound A 34.503 0.055 0.213
GBP: Gabapentin
Table 14: Peak purity of GBP data from control sample
Sample ID RT Peak purity
Purity angle Purity threshold
GBP 6.682 0.583 0.665
GBP-related compound A 34.512 0.560 0.636
GBP: Gabapentin
Selectivity of the method has been established by injecting the following:
a. Standard and test solutions, prepared as per test method as a part 
of identification.
b. Blank and placebo solutions to check any interference of peaks from 
these solutions with that of the analyte peaks.
c. All the related substances solutions individually to confirm the 
retention times.
d. Control Sample (capsule sample) and Spiked Sample (Sample spiked 
with all known related substances at specification level).
e. GBP to confirm the retention time.
The data are represented in Tables 13 and 14.
Table 12: LOD and LOQ for GBP,GBP-related compound A
S. No. Impurity name LOD (µg/mL) LOQ (µg/mL)
1. GBP-related compound A 0.166 0.503
2. GBP 2.244 6.801
LOD: Limit of detection, LOQ: Limit of quantification, GBP: Gabapentin
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Table 15: Stability of GBP-related compound A (standard)
Sample ID Area of GBP-related compound A
Area % Difference
Initial 651,914 -
After 2 h 651,434 0.1
After 4 h 650,035 0.3
After 6 h 651,434 0.1
After 8 h 648,785 0.5
After 10 h 648,152 0.6
After 12 h 648,162 0.6
After 14 h 648,386 0.5
After 16 h 646,013 0.9
After 18 h 645,712 1.0
After 20 h 651,501 0.1
After 22 h 648,538 0.5
After 24 h 648,302 0.6
GBP: Gabapentin
Table 16: Stability of GBP (standard)
Sample ID Area of GBP
Area % Difference
Initial 34,690 -
After 2 h 35,056 -1.1
After 4 h 35,141 -1.3
After 6 h 35,069 -1.1
After 8 h 35,008 -0.9
After 10 h 35,047 -1.0
After 12 h 35,164 -1.4
After 14 h 35,273 -1.7
After 16 h 35,513 -2.4
After 18 h 35,187 -1.4
After 20 h 35,417 -2.1
After 22 h 35,435 -2.1
After 24 h 35,433 -2.1
GBP: Gabapentin
Table 17: Stability of GBP-related compound A (sample)
Sample ID Area of GBP-related compound A
Area % Difference
Initial 45,116 -
After 2 h 45,100 0.0
After 4 h 44,934 0.4
After 6 h 45,703 −1.3
After 8 h 45,029 0.2
After 10 h 45,645 −1.2
After 12 h 45,065 0.1
After 14 h 45,669 −1.2
After 16 h 45,944 −1.8
After 18 h 46,084 −2.1
After 20 h 44,823 0.6
After 22 h 46,532 −3.1
After 24 h 46,518 −3.1
GBP: Gabapentin
Table 18: Stability of GBP (sample)
Sample ID Area of GBP
Area % Difference
Initial 16,706,661 -
After 2 h 16,715,428 −0.1
After 4 h 16,723,944 −0.1
After 6 h 16,718,998 −0.1
After 8 h 16,707,811 0.0
After 10 h 16,705,271 0.0
After 12 h 16,716,568 −0.1
After 14 h 16,720,348 −0.1
After 16 h 16,730,682 −0.1
After 18 h 16,792,874 −0.5
After 20 h 16,818,753 −0.7
After 22 h 16,795,617 −0.5
After 24 h 16,728,026 −0.1
GBP: Gabapentin
Robustness
In analytical technique, robustness was established by infusing system 
suitability solution and sample solution added with other known 
related substances at particular specification level into HPLC under 
deliberately modified chromatographic conditions. The results from 
system suitability and spiked sample were meeting the acceptance 
criteria at each of the variable condition, and the results have been 
presented in Tables 19 and 20.
System suitability
To confirm the suitability of the chromatographic system described 
under the technique which is analyzed by establishing system suitability 
parameters such as percentage RSD and tailing factor. Standard was 
prepared and injected into chromatography as per methodology on a 
Stability of analytical solutions
Stability of standard and test solutions at room temperature (25°C) 
was established by injecting the standard, and test solutions were 
made according to test technique at various time intervals by keeping 
all the standard and test solutions at room temperature (~25°C). GBP 
area in standard solution was measured, and the difference in the area 
was calculated. The areas of known and unknown related substances 
in sample solution were measured, and the percentage differences 
of areas were calculated. The values for the stability of standard and 
samples solutions have been presented in Tables 15-18.
Table 19: Result from standard - system suitability solution






STP Actual 1.1 0.4 0.4
Flow rate (mL/min) 1.3 1.1 0.3 0.1
1.7 1.1 0.3 0.1
% organic composition 
(solution: Acetonitrile)
720:280 1.1 0.3 0.2
680:320 1.1 0.3 0.1
Column oven 
temperature (°C)
20 1.1 0.4 0.2
30 1.1 0.3 0.1
Wavelength (nm) Actual 1.1 0.6 0.5
208 1.1 1.2 0.3
212 1.1 1.0 0.9
GBP: Gabapentin, RSD: Relative standard deviation
Table 20: Result from spiked sample
Condition Variation GBP-related compound A 
retention time
STP Actual 34.747
Flow rate (mL/min) 1.3 36.690
1.7 33.067
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daily basis. The tailing factor for GBP extent in the standard was not 
>2.0, and the results are shown in Table 21.
CONCLUSION
The literature survey indicates that several techniques have been 
already reported for the estimation of GBP in various dosage forms. 
However, very little information has been reported for excipient 
compatibility and related substances of GBP.
The literature survey indicates that when lactose monohydrate, maize 
starch was used as an excipient for GBP, it produced degradation 
product called lactam by Maillard-type condensation reaction due to 
the presence of more water content and hence water activity.
Hence, an effort has been made to find an RP-HPLC technique for 
studying excipient compatibility and related substances of GBP in 
capsule dosage form by using excipients such as lactose anhydrous and 
dried maize starch which is having less water activity.
A RP-HPLC technique is initiated for the estimation of related 
substances of GBP in the capsule dosage form. Waters Alliance e2695 
separation module with UV/photodiode array (PDA) detector with 
Inertsil C8 (250 mm×4.6 mm); 5 µm with an injection volume of 
50 µl is injected and eluted with the (Gradient program) mobile phase 
A buffer: acetonitrile (940:60) and mobile phase B buffer: Acetonitrile 
ACN (700:300) pH 6.9 with 5 N potassium hydroxide which is pumped at 
a flow rate of 1.5 mL/min and detected by UV/PDA detector at 210 nm. 
The peaks of GBP and GBP-related compound A are well separated at 
6.7 min and 34.5 min, respectively.
The developed technique is validated for various parameters according 
to the ICH guidelines such as linearity, accuracy, precision, intermediate 
precision, specificity, range, robustness, LOD, LOQ, stability, and system 
suitability. The results got were according to the acceptance criteria.
The proposed technique is assured for detection of related substances 
in marketed formulation. Hence, the proposed technique observed to 
be agreeable and could be utilized for the routine analysis of GBP and 
GBP-related compound A in the capsule dosage form.
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